Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_2
3
33%
Ph phase_1
5
56%
Ph phase_3
1
11%

Phase Distribution

5

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
5(55.6%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

16.7%

1 of 6 finished

Non-Completion Rate

83.3%

5 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(1)
Terminated(5)
Other(3)

Detailed Status

Withdrawn4
unknown2
Terminated1
Completed1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (55.6%)
Phase 23 (33.3%)
Phase 31 (11.1%)

Trials by Status

unknown222%
withdrawn444%
terminated111%
completed111%
suspended111%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

NCT02620865
withdrawnphase_2

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

NCT00310128
withdrawnphase_2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

NCT00253526
withdrawnphase_1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00024115
withdrawnphase_1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

NCT00052403
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT02620865Phase 1

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Completed
NCT00310128Phase 2

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Withdrawn
NCT00253526Phase 2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn
NCT00024115Phase 1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Withdrawn
NCT00052403Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Withdrawn
NCT00324831Phase 3

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Suspended
NCT00002482Phase 1

Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer

Unknown
NCT00265928Phase 2

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Terminated
NCT00515892Phase 1

Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

Unknown

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9